GNLX - Genelux Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.31 (-1.09%)
At close: 04:00PM EDT
27.31 -0.77 (-2.74%)
After hours: 06:31PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close28.39
Bid26.00 x 800
Ask29.62 x 800
Day's Range27.32 - 29.48
52 Week Range5.35 - 39.27
Avg. Volume55,966
Market Cap692.602M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GNLX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Why Shares of Genelux Corporation Jumped This Week

    Shares of Genelux Corporation (NASDAQ: GNLX) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The company's lead therapy, Olvi-Vec (olvimulogene nanivacirepvec), is a chemotherapy drug that did well in a phase 2 trial to treat heavily pretreated patients with platinum-resistant or refractory ovarian cancer. The results, published in JAMA Oncology, said the therapy showed a 54% objective response rate in a trial of 27 patients.

  • GlobeNewswire

    Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology

    Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising progression-free survivalDemonstrated clinical reversal of platinum resistance and refractoriness Phase 3 OnPrime/GOG-3076 randomized active-controlled registrational trial in collaboration with GOG Foundation/Partners is currently enrolling The Article was featured on JAMA Oncology’s podcast with lead investigator,

  • GlobeNewswire

    Genelux Corporation Announces $33 Million Private Placement

    WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux. Proceeds from the private placement, combined with the current cash and cash equivalents, are expected to extend Genelux’ cash runway in

  • GlobeNewswire

    Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

    WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on Wednesday, March 29, 2023 to commemorate its initial public offering, whi

  • GlobeNewswire

    Genelux Corporation Announces Pricing of Initial Public Offering

    WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.00 per share, for total gross proceeds of approximate